Sweden’s Omnio

Omnio is a biotech startup focused on developing innovative therapies for chronic wounds. Their plasminogen-based therapy aims to address the challenges of hard-to-heal wounds.

Chronic wounds, such as diabetic ulcers, often fail to heal due to underlying conditions and lack of effective treatments. Current therapies may not address the root causes or may have limited efficacy.

Omnio's plasminogen-based therapy leverages the body's natural healing processes to promote wound repair. This approach targets the underlying issues causing chronic wounds, offering a potential breakthrough in treatment.

The target customers include patients with chronic wounds, healthcare providers, and medical institutions specializing in wound care.

Omnio plans to generate revenue through the sale of their therapy once it is approved and commercialized. They may also collaborate with healthcare providers and research institutions.

Omnio has raised a total of €7.2 million in funding, including a recent €2.9 million round and a previous €4.3 million round.

Competitors include companies developing wound care therapies, such as Smith & Nephew, 3M, and other biotech firms in the wound healing space.

The increasing prevalence of chronic diseases, such as diabetes, has led to a higher incidence of chronic wounds. Advances in biotechnology and regenerative medicine have also created opportunities for innovative therapies.